aid: forty-seven-2
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven-2.png
name: Forty Seven 2
description: Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company
  developing therapies that target cancer immune-evasion pathways, based on technology licensed
  from Stanford University. Its lead program, magrolimab, was a monoclonal antibody against the
  CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia,
  non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the
  company completed an IPO in 2018 and was acquired by Gilead Sciences in 2020 for approximately
  $4.9 billion, becoming a wholly-owned Gilead subsidiary. As a therapeutics developer it exposes
  no public developer platform, API, or SDK surface; its former site (fortyseveninc.com) now
  redirects to gilead.com.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven-2/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-note: Acquired by Gilead Sciences in 2020 (~$4.9B); biopharma therapeutics developer with
  no public API/developer surface. The "2" suffix is a portfolio-scraper dedup artifact.
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Immuno-Oncology
- Healthcare
- Clinical-Stage
- Acquired
- Life Sciences
apis: []
common:
- type: Website
  url: https://www.gilead.com/
- type: CrunchBase
  url: https://www.crunchbase.com/organization/forty-seven-inc
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1